IL287477A - Anti-cd38 antibodies and formulations - Google Patents

Anti-cd38 antibodies and formulations

Info

Publication number
IL287477A
IL287477A IL287477A IL28747721A IL287477A IL 287477 A IL287477 A IL 287477A IL 287477 A IL287477 A IL 287477A IL 28747721 A IL28747721 A IL 28747721A IL 287477 A IL287477 A IL 287477A
Authority
IL
Israel
Prior art keywords
antibodies
formulations
Prior art date
Application number
IL287477A
Other languages
Hebrew (he)
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of IL287477A publication Critical patent/IL287477A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
IL287477A 2019-04-23 2021-10-21 Anti-cd38 antibodies and formulations IL287477A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962837518P 2019-04-23 2019-04-23
US201962859699P 2019-06-10 2019-06-10
EP20305145 2020-02-17
EP20305146 2020-02-17
PCT/US2020/029531 WO2020219681A1 (en) 2019-04-23 2020-04-23 Anti-cd38 antibodies and formulations

Publications (1)

Publication Number Publication Date
IL287477A true IL287477A (en) 2021-12-01

Family

ID=70739160

Family Applications (1)

Application Number Title Priority Date Filing Date
IL287477A IL287477A (en) 2019-04-23 2021-10-21 Anti-cd38 antibodies and formulations

Country Status (14)

Country Link
EP (1) EP3958898A1 (en)
JP (1) JP2022529502A (en)
KR (1) KR20220003562A (en)
CN (1) CN114269375A (en)
AU (1) AU2020261039A1 (en)
BR (1) BR112021021060A2 (en)
CA (1) CA3137365A1 (en)
CO (1) CO2021015462A2 (en)
IL (1) IL287477A (en)
MA (1) MA55761A (en)
MX (1) MX2021012967A (en)
SG (1) SG11202111602YA (en)
TW (1) TW202104269A (en)
WO (1) WO2020219681A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024023843A1 (en) * 2022-07-26 2024-02-01 Dr. Reddy’S Laboratories Limited A pharmaceutical formulation of a therapeuticantibody and preparations thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2801583T3 (en) 2004-07-10 2018-07-16 Fox Chase Cancer Center Genetically modified human natural killer cell lines
EP1914242A1 (en) * 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer

Also Published As

Publication number Publication date
EP3958898A1 (en) 2022-03-02
CO2021015462A2 (en) 2021-12-10
CN114269375A (en) 2022-04-01
WO2020219681A1 (en) 2020-10-29
AU2020261039A1 (en) 2021-12-09
JP2022529502A (en) 2022-06-22
KR20220003562A (en) 2022-01-10
MA55761A (en) 2022-03-02
BR112021021060A2 (en) 2021-12-14
TW202104269A (en) 2021-02-01
SG11202111602YA (en) 2021-11-29
CA3137365A1 (en) 2020-10-29
MX2021012967A (en) 2022-01-18

Similar Documents

Publication Publication Date Title
IL276950A (en) Anti-cd73 antibodies and uses thereof
IL278924A (en) Antibodies specific for gucy2c and uses thereof
IL282968A (en) Anti-nkg2a antibodies and uses thereof
IL290141A (en) Anti-pvrig antibodies formulations and uses thereof
IL289585A (en) Dll3-targeting antibodies and uses thereof
IL275826A (en) Anti-mct1 antibodies and uses thereof
EP3773718A4 (en) Compositions and methods comprising anti-nrp2 antibodies
IL286100A (en) Anti-il-36r antibody formulations
IL281297A (en) Anti-npr1 antibodies and uses thereof
EP4037711A4 (en) Compositions and methods comprising anti-nrp2 antibodies
IL277330A (en) Anti-il-27 antibodies and uses thereof
SG11202112112UA (en) Anti-galectin-9 antibodies and uses thereof
EP3580236A4 (en) Anti-g-csf antibodies and uses thereof
IL287690A (en) Anti-hvem antibodies and use thereof
IL280321A (en) Anti-cxcr2 antibodies and uses thereof
IL291027A (en) Anti-steap1 antibodies and uses thereof
IL289656A (en) Anti-tigit antibodies and application thereof
IL291131A (en) Anti-il-23p19 antibody formulations
IL288153A (en) Stabilized formulations containing anti-angptl3 antibodies
IL280281A (en) Anti-cd40 antibodies and uses thereof
IL281976A (en) Anti-fgfr2 antibody formulations
IL283875A (en) Anti-il-27 antibodies and uses thereof
IL281202A (en) Anti-tnfrsf9 antibodies and uses thereof
IL277075A (en) Anti-phf-tau antibodies and uses thereof
IL276548A (en) Bcma-binding antibodies and uses thereof